Roche Financials

CHF48.1 B

Revenue FY, 2015

CHF213.9 B

Mkt cap, 22-Mar-2017
Revenue growth (FY, 2014 - FY, 2015), %1%
Gross profit (FY, 2015)32.7 B
Gross profit margin (FY, 2015), %68%
Net income (FY, 2015)9.1 B
Closing share price, 22-Mar-2017250.1

Financials

Market Value

Revenue/Financials

Income Statement

Annual

CHFFY, 2013FY, 2014FY, 2015

Revenue

46.8 b47.5 b48.1 b

Revenue growth, %

1%1%

Cost of goods sold

11.9 b13.4 b15.5 b

Gross profit

34.8 b34.1 b32.7 b

Gross profit Margin, %

74%72%68%

Sales and marketing expense

8.4 b8.7 b8.8 b

R&D expense

9.3 b9.9 b9.6 b

General and administrative expense

2.6 b3.8 b2.7 b

Operating expense total

20.3 b22.4 b21.1 b

Interest expense

1.6 b1.8 b1.6 b

Interest income

119 m246 m260 m

Income tax expense

(3.3 b)(3 b)(2.9 b)

Net Income

11.4 b9.5 b9.1 b

Cash Flow

Annual

CHFFY, 2013FY, 2014FY, 2015

Cash From Operating Activities

15.8 b15.9 b15.3 b

Operating Metrics

Y, 2014Y, 2015Y, 2016

US FDA Breakthrough Therapy Designations

345

Drugs Approved by FDA

2

Major Approvals (US, EU, JP)

512